Cardiovascular and oncological diseases — focus on modifiable risk factors and modern pathogenetic aspects
暂无分享,去创建一个
E. U. Asymbekova | E. Golukhova | I. Stilidi | E. Artamonova | E. Tugeeva | F. R. Akildzhonov | J. I. Buziashvili | S. T. Mackeplishvili | A. A. Rakhmanzhanov
[1] J. Borrás,et al. Ten-Year Probabilities of Death Due to Cancer and Cardiovascular Disease among Breast Cancer Patients Diagnosed in North-Eastern Spain , 2022, International journal of environmental research and public health.
[2] K. Katanoda,et al. Long-Term Projections of Cancer Incidence and Mortality in Japan and Decomposition Analysis of Changes in Cancer Burden, 2020–2054: An Empirical Validation Approach , 2022, Cancers.
[3] C. Relton,et al. Sex steroid hormones and risk of breast cancer: a two-sample Mendelian randomization study , 2022, Breast Cancer Research.
[4] Weihong Ren,et al. Role of myeloid-derived suppressor cells in the formation of pre-metastatic niche , 2022, Frontiers in Oncology.
[5] Samuel L. Ricci,et al. Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma , 2022, Cancers.
[6] G. Boriani,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal.
[7] Cui Li,et al. New insights into the prognosis of intraocular malignancy: Interventions for association mechanisms between cancer and diabetes , 2022, Frontiers in Oncology.
[8] H. Wang,et al. Risk Factors for the Comorbidity of Hypertension and Renal Cell Carcinoma in the Cardio-Oncologic Era and Treatment for Tumor-Induced Hypertension , 2022, Frontiers in Cardiovascular Medicine.
[9] A. Hormati,et al. Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide , 2022, Middle East journal of digestive diseases.
[10] E. Duplus,et al. Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target , 2021, International journal of molecular sciences.
[11] Mingyue Zhu,et al. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma , 2021, Frontiers in Oncology.
[12] D. Duplyakov,et al. Сonsensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy , 2021, Russian Journal of Cardiology.
[13] K. Sankaranarayanan,et al. Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases—an updated systematic review , 2021, Journal of Genetic Engineering and Biotechnology.
[14] A. Dopazo,et al. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction. , 2021, Journal of the American College of Cardiology.
[15] Karolina Krupa-Kotara,et al. Impact of obesity on risk of cancer. , 2021, Central European journal of public health.
[16] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[17] D. Hedeker,et al. Impact of post-diagnosis weight change on survival outcomes in Black and White breast cancer patients , 2021, Breast cancer research : BCR.
[18] B. Sipos,et al. Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma , 2020, Journal of gastroenterology and hepatology.
[19] Jeroen J. Bax,et al. The cancer patient and cardiology , 2020, European journal of heart failure.
[20] L. Kritharides,et al. Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab , 2020, Journal of clinical medicine.
[21] S. Larsson,et al. Smoking, alcohol consumption, and cancer: A mendelian randomisation study in UK Biobank and international genetic consortia participants , 2020, PLoS medicine.
[22] K. Guan,et al. Role of Leptin in Cardiovascular Diseases , 2020, Frontiers in Endocrinology.
[23] S. Shankar,et al. The Impact of obesity and diabetes mellitus on pancreatic cancer: Molecular mechanisms and clinical perspectives , 2020, Journal of cellular and molecular medicine.
[24] Adenike O Eketunde. Diabetes as a Risk Factor for Breast Cancer , 2020, Cureus.
[25] B. Perillo,et al. ROS in cancer therapy: the bright side of the moon , 2020, Experimental & Molecular Medicine.
[26] Prakash Kulkarni,et al. The Mitochondrion as an Emerging Therapeutic Target in Cancer. , 2020, Trends in molecular medicine.
[27] Lei Deng,et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. , 2019, European heart journal.
[28] P. Libby,et al. Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.
[29] F. Greten,et al. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. , 2019, Immunity.
[30] S. Reddy,et al. HDL and LDL: Potential New Players in Breast Cancer Development , 2019, Journal of clinical medicine.
[31] D. Crossman,et al. Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS). , 2018, Journal of thoracic disease.
[32] Jennifer R. Grandis,et al. Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.
[33] R. Levine,et al. Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. , 2018, Cell stem cell.
[34] Xinqiang Han,et al. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy , 2017, npj Precision Oncology.
[35] Y. Abed,et al. Obesity and inflammation: the linking mechanism and the complications , 2016, Archives of medical science : AMS.
[36] O. Tangvarasittichai,et al. Tumor Necrosis Factor-Α, Interleukin-6, C-Reactive Protein Levels and Insulin Resistance Associated with Type 2 Diabetes in Abdominal Obesity Women , 2016, Indian Journal of Clinical Biochemistry.
[37] Yi-Min Zhu,et al. Diabetes and cancer: Associations, mechanisms, and implications for medical practice. , 2014, World journal of diabetes.
[38] R. Gottlieb,et al. Mitochondrial therapeutics for cardioprotection. , 2011, Current pharmaceutical design.
[39] A. Jemal,et al. The global burden of cancer: priorities for prevention , 2009, Carcinogenesis.
[40] A. Dispenzieri,et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.
[41] U. Goldbourt,et al. Is there an association between hypertension and cancer mortality? , 2002, The American journal of medicine.
[42] Sadeer G. Al-Kindi,et al. Prevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer: The Unmet Need for Onco-Cardiology. , 2016, Mayo Clinic proceedings.